Plain-English translation of NCT06374459 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new medication called zunsemetinib paired with an existing chemotherapy drug called in people with advanced breast cancer that has spread to their bones. The study is divided into two phases: first, researchers will find the safest dose of the new medication to use alongside , then they'll test whether this combination works better than standard treatment. The goal is to help people whose cancer has grown despite previous hormone therapies.
Bone metastasis (cancer that has spread to the bones) is a common and serious form of advanced breast cancer, and many patients stop responding to standard hormone treatments. This trial exists to see whether adding this medication to chemotherapy might help control the cancer better and improve quality of life for these patients.
You likely qualify if…
You likely don't qualify if…
You will take the new medication by mouth twice daily and on a 14-days-on, 7-days-off schedule in 21-day treatment cycles. The first phase of the trial involves finding the right dose, so early participants may receive different doses than later ones. You'll have regular clinic visits for blood tests, physical exams, and imaging scans to monitor how the cancer is responding. The study is recruiting 152 participants total and is sponsored by Washington University School of Medicine.
AI-generated summary from trial data · Jun 30, 2026 · Not medical advice
United States